Evidence map›Paper›PMID 29641417›Full record

ReviewDevelopmental period medicine

[Fragile X syndrome and FMR1-dependent diseases - clinical presentation, epidemiology and molecular background].

Aleksandra Landowska, Sylwia Rzońca, Jerzy Bal, Monika Gos

Open access · greenAbstract readReview
In one paragraph

Review in Developmental period medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aleksandra LandowskaZakład Genetyki Medycznej, Instytut Matki i Dziecka, Warszawa, Polska.
Sylwia RzońcaZakład Genetyki Medycznej, Instytut Matki i Dziecka, Warszawa, Polska.
Jerzy BalZakład Genetyki Medycznej, Instytut Matki i Dziecka, Warszawa, Polska.
Monika GosZakład Genetyki Medycznej, Instytut Matki i Dziecka, Warszawa, Polska.
Instytut Matki i Dziecka · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragile X syndrome (FXS) is the second most common inherited cause of intellectual disability (ID), after Down syndrome. The severity of ID in FXS patients varies and depends mainly on the patient's sex. Besides intellectual disorders, additional symptoms, such as psychomotor delay, a specific behavioral phenotype, or emotional problems are present in FXS patients. In over 99% of the cases, the disease is caused by the presence of a dynamic mutation in the FMR1 gene localized on the X chromosome. Due to the expansion of CGG nucleotides (over 200 repeats), FMR1 gene expression is decreased and results in the significant reduction of the FMRP protein level. The CGG expansion to premutation range (55-200 CGG repeats) is equivalent to the FXS carrier status and may cause FMR1-dependent disorders - fragile X-associated primary ovarian insufficiency (FXPOI) and fragile X-associated tremor/ataxia syndrome (FXTAS). In contrast to FXS, clinical symptoms of these diseases occur later in adulthood. The aim of the article is to present the knowledge about the molecular background and epidemiology of fragile X syndrome and other FMR1-related disorders.

Indexed as

DNA Repeat ExpansionGene Expression RegulationAtaxiaFemaleFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansMaleMutationPrimary Ovarian InsufficiencyTremorFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1FMR1fragile X syndromeFXPOIFXSFXTAS

Identifiers

PMID29641417
PMCPMC8522919
OpenAlexW2969381915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.